Below are a collection of excerpts from biomedical research articles. Excerpts are separated by newlines. Your task is to answer a question based these excerpts. Your response should be formatted as a `json` array.

For instance, given excerpts from articles studying breast cancer, and the question "what are some common genes associated with breast cancer?", an answer might be formatted like: ["BRCA1", "BRCA2", "TP53", ...]. Only include answers that are mentioned in the provided exerpts. The array should always have at least one answer; do not respond with an empty array []. Do not include any text in your response other than the answer array.

Context: Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD).
On the basis of the strong association of IL-33 pathway genes with pulmonary diseases like asthma and COPD, we conducted this phase 2a trial to assess the safety and efficacy of itepekimab in patients with moderate-to-severe COPD on a stable regimen of triple-inhaled or double-inhaled background maintenance therapy.
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
INTERPRETATION: The primary endpoint in the overall population was not met, subgroup analysis showed that itepekimab reduced exacerbation rate and improved lung function in former smokers with COPD.
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.
CONCLUSIONS: Interleukin-33 blockade with itepekimab led to a lower incidence of events indicating a loss of asthma control than placebo and improved lung function in patients with moderate-to-severe asthma.
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first-in-human and first-in-patient trials.
Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD).
ptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary diseas
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
with the combination therapy. Itepekimab treatment improved asthma control and quality of life, as compared with placebo, and led to a greater reduction in th
[95% CI 0·01-0·10], p=0·024). When analysis was restricted to former smokers, treatment with itepekimab was associated with nominally significant reductions in acute exacerbations of COPD (RR 0·58 [95% CI 0·39-0·85], p=0·0061) and FEV1 improvement (least squares mean difference 0·09 L [0·02-0·15], p
racterised for COPD. We then did a double-blind, phase 2a trial comparing itepekimab with placebo in patients with moderate-to-severe COPD despite standard therapy, at 83 study si

Question:
Which diseases can be treated with Itepekimab?
["asthma", "chronic obstructive pulmonary disease"]